Clinicians should be aware of a possible association between HS and inflammatory eye disease, perhaps arising from an immune dysregulation phenomenon similar to that which links Crohn’s and HS.
Advances in Biologic Therapies for IMIDs
After two decades of using biologics for IMIDs, we now have an armamentarium, including five drugs and a number of biosimilars, that continues to grow at a record pace.
Assessing Progressive Multifocal Leukoencephelopathy Risk in Patients Treated with Immunosuppressives
One of the most feared risks of immunosuppressive and biologic therapeutics is the development of progressive multifocal leukoencephelopathy. A risk assessment tool is available.